Product Details
| Alternative Name: | ARG1 |
| |
| Source: | Produced in E. coli. Full length human arginase I. |
| |
| EC: | 3.5.3.1 |
| |
| UniProt ID: | P05089 |
| |
| Formulation: | Liquid. In 10mM TRIS-HCl, pH 7.5, containing 1mM β-mercaptoethanol, 1mM MnCl2 and 50% glycerol. |
| |
| Purity: | ≥90% (SDS-PAGE) |
| |
| Specific Activity: | ~2.0U/µg protein. One unit is defined as the amount of enzyme that converts 1µmol of L-arginine to L-ornithine and urea per min. at 37°C, pH 9.5 (R.T. Schminke, et al.; J. Biol. Chem. 238, 1012 (1962)). |
| |
| Shipping: | Dry Ice |
| |
| Long Term Storage: | -80°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment: S.M. Steggerda, et al.; J. Immunother. Cancer
5, 101 (2017),
Abstract;
Full Text
Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells: E. Sandalova, et al.; Gastroenterology
143, 78 (2012),
Abstract;
Biodegradable chitosan particles induce chemokine release and negligible arginase-1 activity compared to IL-4 in murine bone marrow-derived macrophages: J. Guzman-Morales, et al.; BBRC
405, 538 (2011),
Abstract;
Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector: C.L. Gau, et al.; Mol. Ther.
17, 1155 (2009),
Abstract;
Arginase 1 is expressed in myelocytes/metamyelocytes and localized in gelatinase granules of human neutrophils: L.C. Jacobsen, et al.; Blood
109, 3084 (2007),
Abstract;
Implications of the S-shaped domain in the quaternary structure of human arginase: A. Mora, et al.; Biochim. Biophys. Acta
1476, 181 (2000),
Abstract;
Determination of arginase activity in macrophages: a micromethod: I.M. Corraliza, et al.; J. Immunol. Methods
174, 231 (1994),
Abstract;
